GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
S

Shanghai Hile Bio-Technology Co 603718.SS · CNY

Health Care · Shanghai · 🇨🇳 China

Compare

3.02

+1.34%

Close of 9 Nov 2026, in CNY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in CNY, from our data supplier.

FY2025

Revenue

CN¥187.9m

FY2016FY2025

Net income

−CN¥311.4m

FY2016FY2025

Free cash flow

CN¥46.7m

FY2016FY2025

Shareholders' equity

CN¥882.0m

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
RevenueCN¥187.9mCN¥271.0mCN¥240.7mCN¥300.0mCN¥347.3mCN¥259.1mCN¥278.0mCN¥254.6mCN¥303.7mCN¥343.3m
Research and developmentCN¥22.7mCN¥32.8mCN¥25.0mCN¥29.9mCN¥28.6mCN¥29.5mCN¥29.6mCN¥27.3mCN¥20.2mCN¥25.1m
Operating incomeCN¥47.1mCN¥177.8mCN¥57.9mCN¥69.9mCN¥57.2m−CN¥5.7mCN¥7.0mCN¥22.2mCN¥114.0mCN¥74.0m
Net income−CN¥311.4mCN¥171.2mCN¥62.9mCN¥121.6mCN¥53.9mCN¥8.9mCN¥12.2mCN¥21.3mCN¥113.7mCN¥85.5m
Diluted earnings per share-0.460.280.100.200.070.010.020.030.180.12

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assetsCN¥1.13bnCN¥1.83bnCN¥1.66bnCN¥1.51bnCN¥1.84bnCN¥1.79bnCN¥1.70bnCN¥1.75bnCN¥1.60bnCN¥1.48bn
Cash and short-term investments—CN¥517.1mCN¥353.2mCN¥392.7mCN¥538.6mCN¥520.7mCN¥595.3mCN¥47.1mCN¥96.3mCN¥284.3m
Total liabilitiesCN¥229.1mCN¥123.6mCN¥483.0mCN¥403.2mCN¥856.9mCN¥824.5mCN¥708.7mCN¥722.8mCN¥526.8mCN¥474.5m
Debt—CN¥49.3mCN¥50.8mCN¥41.2mCN¥14.6mCN¥466.9mCN¥427.7mCN¥50.0mCN¥180.0mCN¥210.8m
Shareholders' equityCN¥882.0mCN¥1.56bnCN¥1.22bnCN¥1.14bnCN¥1.01bnCN¥1.06bnCN¥1.06bnCN¥1.06bnCN¥1.07bnCN¥981.6m
Shares outstanding674m616m647m610m761m1,639m498m642m644m687m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operationsCN¥58.8mCN¥46.5m−CN¥2.9mCN¥292.9mCN¥43.6mCN¥167.7mCN¥59.3mCN¥18.9mCN¥34.9mCN¥108.4m
Capital spending−CN¥12.2m−CN¥8.4m−CN¥7.8m−CN¥19.8m−CN¥37.8m−CN¥34.1m−CN¥39.0m−CN¥112.3m−CN¥86.0m−CN¥136.2m
Free cash flowCN¥46.7mCN¥38.1m−CN¥10.8mCN¥273.1mCN¥5.9mCN¥133.6mCN¥20.2m−CN¥93.4m−CN¥51.1m−CN¥27.8m
Dividends paid−CN¥122.3m−CN¥21.6m−CN¥36.5m−CN¥683,937−CN¥2.7m−CN¥3.9m−CN¥6.4m−CN¥39.8m−CN¥35.6m−CN¥35.6m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
RevenueCN¥88.5mCN¥47.4mCN¥38.1mCN¥40.0mCN¥48.0mCN¥61.8mCN¥96.6mCN¥66.8m
Operating incomeCN¥14.2mCN¥11.2mCN¥9.1mCN¥7.4mCN¥15.7mCN¥20.9mCN¥201.9m−CN¥8.1m
Net incomeCN¥5.1mCN¥6.3m−CN¥331.8mCN¥2.1mCN¥7.3mCN¥10.9mCN¥151.0mCN¥5.0m
Diluted earnings per share0.010.01-0.490.000.010.020.250.01
Cash from operations———−CN¥1.0mCN¥43.0m−CN¥4.0m—CN¥12.0m
Capital spending−CN¥3.0m—−CN¥5.0m—−CN¥2.0m−CN¥4.0m−CN¥1.0m—
Free cash flow————CN¥41.0m−CN¥8.0m——
Total assetsCN¥1.38bnCN¥1.25bnCN¥1.13bnCN¥1.80bnCN¥1.84bnCN¥1.83bnCN¥1.83bnCN¥1.62bn
Cash and short-term investments———CN¥470.3mCN¥515.8mCN¥475.8mCN¥517.1mCN¥221.2m
DebtCN¥45.6mCN¥56.3m—CN¥7.0m———CN¥53.9m
Shareholders' equityCN¥892.9mCN¥886.3mCN¥882.0mCN¥1.53bnCN¥1.58bnCN¥1.58bnCN¥1.56bnCN¥1.27bn

Financial ratios

Data as of 24 Oct 2026

FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Operating margin-97.7%78.8%25.5%47.2%20.1%-2.2%—
Net margin-165.8%63.2%26.1%40.5%15.5%3.4%—
Return on equity-35.3%11.0%5.2%10.7%5.4%0.8%—
Return on assets-27.7%9.4%3.8%8.0%2.9%0.5%—
Free cash flow yield3.7%3.1%0.3%17.8%3.7%4.3%—
Revenue growth-30.7%12.6%-19.8%-13.6%34.0%-6.8%—
Earnings growth-281.9%172.3%-48.3%125.8%503.3%-26.5%—
Current ratio5.34x6.90x1.35x2.07x1.46x1.16x—
Debt to equity—0.02x0.04x0.02x0.01x0.44x0.40x
Equity ratio78.4%85.4%73.4%75.3%54.5%59.2%—
Interest coverage-145.19x38.90x11.40x13.73x5.56x-0.32x—
R&D as a share of sales12.1%12.1%10.4%10.0%8.2%11.4%—
Buybacks as a share of market value-9.4%4.8%-6.1%19.8%53.6%-229.1%—

Growth per year

Compound annual rate

3 years5 years10 years
Revenue-14.4%-6.2%-5.1%
Operating income-12.4%—-8.1%

Average margins

Over each period

1 year3 years5 years10 years
Operating margin49.0%35.3%25.2%23.6%
Net margin-30.6%4.4%6.7%14.0%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings-13.224.9110.349.3216.2——381.562.5143.2
Price to sales21.915.728.820.033.579.722.931.923.435.7

Dividends and splits

Per share, in the currency the company pays

Paid for 3 years. Last went ex-dividend on 15 Jul 2025.

FY2025FY2024FY2023FY2021FY2020FY2019FY2018FY2017
Paid in the year0.0780.0290.0570.0040.0060.010.0550.04

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.